Meningococcal B Vaccine in Patients With Asplenia

• ClinicalTrials.gov Identifier: NCT06025487
• Recruitment Status: Not yet recruiting
• First Posted: September 6, 2023
• Last Update Posted: September 6, 2023
• Sponsor: Medical University of Vienna
• Information provided by (Responsible Party): Nicole Harrison, Medical University of Vienna

Study Description

Brief Summary:

Patients without a spleen (asplenia) experience an increased risk for septicaemia from encapsulated bacteria, which is associated with a high mortality rate. Meningococcal bacteria can cause such infections and serogroup B is the dominant meningococcal subtype in Europe. Therefore, vaccination for risk populations like patients without a spleen is a pressing matter. Considering the effectiveness of the meningococcal serogroup B vaccine, data for this high-at-risk population is currently lacking. The aim of this study is to evaluate the meningococcal B vaccine (BEXSERO®) in patients without a spleen compared to a healthy control group. A total of 40 patients and 40 healthy persons will receive a two-dose schedule of BEXSERO® with a one-month interval between doses. The effectiveness of the vaccine will be determined by measuring antibodies against different meningococcal strains in the blood of the patient. The amount of antibodies one month after second vaccination will be compared between patients and healthy persons. The most reliable assay to determine antibodies against meningococcal strains is the human serum bactericidal assay which will be carried out in a reference laboratory. Other end points are the persistence of antibodies after six months and the cellular immune response. The cellular immune response will be assessed by measuring the proliferation of certain immune cells like lymphocytes and the amount of produced cytokines (signalling proteins) after vaccination. In addition, the safety of the vaccine will be evaluated by documenting all adverse reactions to the vaccine. Overall, this study will be the first to assess the effectiveness of the meningococcal B vaccine in this high-at-risk population and provide data for vaccination guidelines.

Condition or disease	Intervention/treatment	Phase
Splenectomy; Status	Biological: Bexsero	Phase 2

Detailed Description:

This study is a prospective open-label phase II pilot study to assess the immunogenicity and safety of BEXSERO® in asplenic patients. Patients participating in the study will complete a total of four study visits. A two dose schedule of BEXSERO® will be applied intramuscularly with a one month interval between doses. Seropositivity will be assessed at baseline during the first visit, one month and six months after the second vaccination. Basic demographic data (gender, age) and medical data (type of asplenia, time of splenectomy, underlying diseases, concurrent medical conditions, medication etc) will be entered into a case report form (CRF). During the second and third visit all adverse events will be entered into the CRF and severe adverse events (SAEs) will be reported accordingly. Patients who have either been splenectomised or suffer from functional asplenia will be recruited for this study during their routine vaccination visit at the out-patient ward for infectious diseases of the Medical University of Vienna. A total of 40 patients and 40 healthy controls will be recruited for this study. The null hypothesis states that the immunogenicity of the meningococcal B vaccine is inferior in asplenic patients compared to a healthy control group. Immunogenicity will be assessed by human serum bactericidal antibody assay (hSBA) against three vaccine antigens. The human serum bactericidal antibody assay (hSBA) will be carried out in a reference laboratory (Meningococcal Reference Unit, Health Protection Agency North West Laboratory, Manchester Royal Infirmary, United Kingdom) to determine functional antibodies against three meningococcal vaccine antigens: PorA (strain NZ98/254), fHbp (strain 44/76-SL) and NadA (strain 5/99). The hSBA measures complement mediated killing of Neisseria meningitidis by vaccine-induced antibodies. It is considered as the "gold standard" for measuring antibody response against meningococcal bacteria. Currently, the detection of antibodies by hSBA with a titre of ≥1:4 is considered as a correlate for protection against meningococcal disease. The primary end point is the mean log-titre over the three meningococcal strains (NZ98/254 for PorA, 5/99 for NadA and 44/76-SL for fHbp) as measured by the hSBA one month after second vaccination. The non-inferiority margin was set to a 2-fold titre difference between the geometric mean titre of the asplenic group and the healthy control group. To investigate cellular immunity following meningococcal vaccination, lymphocyte proliferation and cytokine detection assays will be used.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 80 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: prospective open-label phase II study comparing patients and healthy controls
• Masking: None (Open Label)
• Primary Purpose: Prevention
• Official Title: Immunogenicity and Safety of a Meningococcal Serogroup B Vaccine in Adult Patients With Asplenia
• Estimated Study Start Date: October 1, 2023
• Estimated Primary Completion Date: June 1, 2025
• Estimated Study Completion Date: June 1, 2025

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Patients; Asplenic patients receiving two doses of Bexsero (meningococcal B vaccine) with one-month interval between doses	Biological: Bexsero; two doses of Bexsero are applied intramuscularly with a one-month interval between doses
Active Comparator: Healthy controls; Healthy controls receiving two doses of Bexsero (meningococcal B vaccine) with one-month interval between doses	Biological: Bexsero; two doses of Bexsero are applied intramuscularly with a one-month interval between doses

Outcome Measures

Primary Outcome Measures :

1. Humoral immunogenicity [ Time Frame: one month after second vaccination ]

   Immunogenicity will be assessed by human serum bactericidal antibody assay (hSBA) against three vaccine antigens (PorA, fHbp and NadA). The primary end point is the mean log-titre over the three meningococcal strains (NZ98/254 for PorA, 5/99 for NadA and 44/76-SL for fHbp) as measured by the hSBA one month after second vaccination.

   The non-inferiority margin was set to a 2-fold titre difference between the geometric mean titre of the asplenic group and the healthy control group.

Secondary Outcome Measures :

1. Persistence of humoral immunity [ Time Frame: six months after second vaccination ]
   The persistence of antibodies six months after second vaccination as measured by hSBA
2. Cellular immunogenicity - lymphocyte proliferation [ Time Frame: one month after second vaccination ]
   The cellular immune response as measured by lymphocyte proliferation assay
3. Cellular Immunogenicity - cytokine levels [ Time Frame: one month after second vaccination ]
   The cellular immune response as measured by cytokine levels using Luminex
4. Adverse Events [ Time Frame: four weeks after first and second vaccination ]
   Evaluation of safety by documenting all adverse events after vaccination

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 60 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

For asplenic patients:

• asplenia due to splenectomy or functional asplenia
• 18 to 60 years of age
• if female: have a negative urine pregnancy test result at study entry and agree to employ adequate birth control measures for the duration of the study
• providing written informed consent

For healthy controls:

• 18 to 60 years of age
• if female: have a negative urine pregnancy test result at study entry and agree to employ adequate birth control measures for the duration of the study
• providing written informed consent

Exclusion Criteria:

For asplenic patients:

• pregnant or lactating
• febrile illness within last two weeks prior to enrolment
• allergic reactions to vaccination in past
• chemotherapy with Rituximab within last six months or during study period
• more than 20mg prednisone per day within last four weeks prior or at the time of enrolment
• previous vaccination against meningococcal serogroup B

For healthy controls:

• pregnant or lactating
• febrile illness within last two weeks prior to enrolment
• allergic reactions to vaccination in past
• any immunosuppressive condition or medication
• previous vaccination against meningococcal serogroup B

Contacts and Locations

Contacts

Contact: Nicole Harrison, Dr.; +43 1 40400 ext 44400; nicole.harrison@meduniwien.ac.at

Sponsors and Collaborators

Medical University of Vienna

Investigators

• Principal Investigator: Nicole Harrison, Dr.; Medical University Vienna

More Information

• Responsible Party: Nicole Harrison, Dr. Nicole Harrison, Consultant for Infectious Diseases and Tropical Medicine, Medical University of Vienna
• ClinicalTrials.gov Identifier: NCT06025487
• Other Study ID Numbers: MenB_Asplenia; 2022-001451-16 ( EudraCT Number )
• First Posted: September 6, 2023
• Last Update Posted: September 6, 2023
• Last Verified: August 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by Nicole Harrison, Medical University of Vienna:

Asplenia; Meningococcal disease; Meningococcal B vaccine